Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $5.50

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received a consensus recommendation of “Hold” from the five analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $5.50.

A number of research firms have commented on MRVI. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Finally, Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the transaction, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.49% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Large investors have recently modified their holdings of the business. Brummer Multi Strategy AB purchased a new stake in Maravai LifeSciences in the 4th quarter valued at approximately $1,488,000. Eversept Partners LP grew its holdings in Maravai LifeSciences by 147.2% during the 4th quarter. Eversept Partners LP now owns 718,582 shares of the company’s stock valued at $2,335,000 after buying an additional 427,909 shares during the last quarter. Capricorn Fund Managers Ltd purchased a new position in Maravai LifeSciences during the first quarter worth $961,000. Tejara Capital Ltd increased its position in Maravai LifeSciences by 23.1% during the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock worth $9,816,000 after buying an additional 566,768 shares in the last quarter. Finally, General American Investors Co. Inc. increased its position in Maravai LifeSciences by 1,062.2% during the fourth quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock worth $5,152,000 after buying an additional 1,448,907 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Stock Down 4.1%

NASDAQ MRVI opened at $6.76 on Thursday. The business’s fifty day simple moving average is $5.56 and its 200-day simple moving average is $4.20. Maravai LifeSciences has a 52 week low of $1.99 and a 52 week high of $7.44. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The firm has a market cap of $1.75 billion, a PE ratio of -9.52 and a beta of 0.65.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. As a group, equities analysts anticipate that Maravai LifeSciences will post -0.2 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.